Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CYB003

Small molecule · developed by Cybin IRL

Phase 3 Most advanced trial
1 Registered trials

What is CYB003?

CYB003 is a deuterated psilocin analog being studied in major depressive disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Psychiatry
Developer
Cybin IRL Limited
In trials of
HELP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
KXD3HS8D6X

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06793397 Phase 3 Major Depressive Disorder (MDD) Recruiting HELP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DepressionDepression - Major Depressive DisorderDepression DisorderDepression in AdultsMajor Depressive Disorder (MDD)

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.